Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 2/3 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Neoplasms 314Carcinoma, Non-Small-Cell Lung 162Breast Neoplasms 125Neoplasm Metastasis 106Melanoma 95Leukemia, Myeloid, Acute 80Lymphoma 79Multiple Myeloma 74Colorectal Neoplasms 73Ovarian Neoplasms 70Lymphoma, Non-Hodgkin 63Recurrence 58Prostatic Neoplasms 56Pancreatic Neoplasms 51Lung Neoplasms 50Carcinoma, Renal Cell 40Glioblastoma 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Lymphoma, Large B-Cell, Diffuse 37Leukemia, Lymphocytic, Chronic, B-Cell 37Advanced Solid Tumors 37Leukemia 36Myelodysplastic Syndromes 35Triple Negative Breast Neoplasms 34Head and Neck Neoplasms 33Sarcoma 31Brain Neoplasms 31Urinary Bladder Neoplasms 30Stomach Neoplasms 30Lymphoma, Follicular 28

Interventions

enzalutamide 1bintrafusp alfa protein, human 1Radiotherapy 1Paclitaxel 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Has results × Camurati-Engelmann Syndrome × Clear all
NCT03685591 2024-06-26

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
49 enrolled 33 charts
BreastDermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma, Breast Neoplasms, Carcinoma, Renal Cell, Camurati-Engelmann Syndrome, Liver Neoplasms, Melanoma, Mesothelioma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

NCT04551950 2024-03-08

Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)

EMD Serono

Phase 1 Completed
25 enrolled 14 charts
Gynecologic

Uterine Cervical Neoplasms, Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡